BioAlta, Inc launches an IPO.

An IPO of BioAtla, Inc. (BCAB) will take place on December 15, 2020. BioAtla is a clinical stage biopharmaceutical company that is developing a new class of highly specific and selective antibody-based therapies for cancer treatment. The proprietary CAB platform for the development of candidate cancer treatment products targets well-known and widely tested tumor antigens that were previously difficult or impossible to target. A key advantage in applying CAB technology to antibodies is that it allows antigens to be selectively targeted to tumor cells and minimizes or eliminates the binding of these antigens to normal cells, thereby reducing toxicity associated with conventional cancer treatment approaches.

The listed bookrunners of the IPO are JP Morgan, Jefferies, Credit Suisse and BTIG.